Verrica Pharmaceuticals (VRCA) investor relations material

Executive summary

• Achieved record growth in YCANTH demand, with 15,302 applicator units dispensed in Q1 2026, up 51.3% year-over-year and 12.1% sequentially, and continued momentum into April.

• YCANTH launched commercially in Japan in February 2026, marking the first ex-U.S. market entry and supporting global expansion.

• Advanced clinical pipeline with over 50% enrollment in the first Phase 3 trial for common warts and progress on VP-315 for basal cell carcinoma.

• Net loss for Q1 2026 was $9.7 million ($0.45 per share), unchanged from Q1 2025, with non-GAAP net loss at $8.8 million ($0.41 per share).

• Cash balance as of March 31, 2026, was $20.6 million, with runway into Q1 2027 but substantial doubt about going concern without additional funding.

Financial highlights

• Q1 2026 total revenue was $5.0 million, including $4.3 million from U.S. YCANTH sales (up 25.4% year-over-year) and $0.7 million from license/collaboration revenue, mainly from the Japan launch.

• U.S. YCANTH dispensed applicator units grew 51.3% year-over-year and 12.1% sequentially from Q4 2025.

• Gross product margin was 87.3% in Q1 2026, slightly down from 87.6% in Q1 2025.

• Operating expenses increased to $14.7 million in Q1 2026, mainly due to higher SG&A and R&D costs.

• Cash used in operating activities was $9.2 million in Q1 2026, down from $12.7 million in Q1 2025.

Outlook and guidance

• Management expects continued growth for the year but did not provide formal guidance.

• Cash is expected to support operations into Q1 2027; additional capital will be needed for ongoing R&D and commercialization.

• Second Phase 3 trial for common warts (COVE-3) expected to initiate by mid-2026 in the U.S. and Japan.

• Preparing for EU regulatory submission for YCANTH, with no further Phase 3 trials required for approval.

• Commercial execution and adoption, especially among pediatricians, are key drivers for future growth.